Background
There are two widely recognized progressive courses predominating in multiple sclerosis (MS) -primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS). PPMS is typified by progression from the clinical onset of MS, whereas SPMS is reached after an initial relapsingremitting (RR) course, with the proportion of patients converting to SPMS increasing over time. Across studies, it is generally agreed that the age at symptom onset for PPMS averages 40 years. 1 For relapsingremitting multiple sclerosis (RRMS), it is approximately 30 years, and from this point forward, these individuals take a median of 20 years to reach SPMS. [1] [2] [3] [4] [5] A very crude estimation would place the average person when reaching SPMS to be around 50 years of age (30 + 20 = 50 years). When appropriate survival analyses have been applied, the estimates have been reported to be between 49 and 53 years, 2,5 almost a decade after the onset of PPMS. So, how has the belief arisen that SPMS and PPMS occur at the same age? Here, we summarize the salient points, including why it matters, and how applying appropriate methods indicates that clinically SPMS and PPMS occur almost a decade apart.
Why does it matter?
Whether PPMS and SPMS represent distinct or overlapping disease process(es) has been debated, with comparisons between the two phases including pathological findings and clinical characteristics, such as the age at onset of progression. 6 A clear understanding of the characteristics of the progressive phases is also important to enable evidenced-based information for individuals with MS as well as to facilitate clinical trial design. For example, clinical trials can benefit from enrolment criteria which target an appropriate group of individuals for inclusion, allowing recruitment to occur within a timely manner and for findings to be applicable to a reasonably wide population. To date, most pharmacological clinical trials have been designed separately for SPMS and PPMS; an indication that the two disease courses are viewed quite differently.
Why have some misguidedly concluded that PPMS and SPMS share a similar onset age? Studies which have reported finding no differences in the age at onset of progression between those with SPMS and PPMS have typically systematically excluded those RR patients who had not (yet) reached SPMS. 7-10 Omitting those patients has led to misleading conclusions. This is particularly problematic as many studies to date comparing the clinical characteristics of PPMS and SPMS are based on cohorts with limited follow-up.
Follow-up time is probably the biggest challenge when comparing the characteristics of PPMS and SPMS from a cohort of prospectively followed patients. Overlooking this issue has led to misleading conclusions. A similar situation would arise if an Expanded Disability Status Scale (EDSS) milestonerelated or mortality study was conducted over a finite period, whereby only those who had reached the disability milestone (e.g. EDSS 6) or who had died by the study end were included, with those not reaching EDSS 6 or who remained alive were ignored.
Consider a cohort of 1000 MS patients followed from disease onset. The 'baseline' characteristics of the 10% (100) PPMS patients will remain static (sex, age at PPMS onset, etc.), while those of the SPMS patients will shift over time as more of the original 90% (900) RR subjects reach SPMS. Comparing across natural history studies, it can be observed that the proportion of patients with RRMS at onset who reach SPMS by the study end increases steadily from 32%, 51%, 58% to 69% after 12, 18, 20 and 25 years of follow-up, respectively. 2,7-9 Moreover, as many are aware, those reaching SPMS earlier are phenotypically different than those who remain in the RR phase for longer. 2 Both sex and the age at MS onset alter the risk and timing of SPMS onset. 1 If the original cohort of 900 RRMS onset patients were followed for a short period of time (e.g. 5 years), 10% (90) might have reached SPMS; 20 years later, this might rise to 50% (450). As the proportion of individuals reaching SPMS increases, so does the femaleto-male ratio, shifting from an estimated 1.6 to 2.1 2 Likewise, the age at which SPMS is reached will shift among the fraction of individuals who reached the outcome by the study end. Failing to take this into account, especially when a high proportion of RRMS patients have yet to reach the SPMS pool, has led to the misconception that the age at onset of SPMS and PPMS was similar. 7-9 There are statistical techniques (survival analyses) which when applied appropriately can take the effects of time into consideration. Specifically, all the relapsing-onset MS individuals must be included -both those already known to have reached SPMS as well as those still in the RR phase who are 'at risk' of reaching SPMS at an unknown time in the future.
Evidence that clinically, the secondaryprogressive phase starts much later than PPMS onset When survival analyses are applied to take into account the possibility the RR patients might develop SPMS, then a noticeable difference between the clinical onset of SPMS and PPMS has emerged. 2, 5, 6 For example, in a cohort of 2837 followed for a mean of 20 years, 1445/2484 (58%) of the RRMS population had reached SPMS by the study close. From Kaplan-Meier analysis, incorporating information from all subjects with RR onset, the estimated median onset age of progression was almost a decade later in SPMS (49.0 years; 95% confidence interval (CI): 48.3-49.7) than PPMS (41.0 years; 95% CI: 39.7-42.4), p < 0.0005. 6 In a 'mock' analysis where the same cohort was taken, but follow-up was shortened (truncated) to 15 years, an age gap remained. 6 However, if then the 35% of the RRMS patients who had not (yet) reached SPMS were omitted, in order to mimic another study which also omitted a similar proportion, 8 then no such difference was observed (p = 0.114). 6 In summary, determining the age at progression onset requires careful consideration of patient ascertainment and wise application of estimation methods. The misconception that PPMS and SPMS share a similar onset age has occurred by either not applying the appropriate survival analyses or erroneously omitting subjects, in particular, excluding those 'at-risk' RRMS individuals yet to reach SPMS.
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Whenever I read natural history studies, I think that they should come with the disclaimer that they are investigating a particular question in a particular setting and that all such studies rest on assumptions that the investigators make.
Maybe the most noticeable conclusion from natural history research is that there is a very wide spectrum ranging from the mildest to the most severe outcomes. Over the last decades, our understanding of this wide spectrum has increased, which unfortunately only made it harder to define what multiple sclerosis (MS) is and where the disease begins. This spectrum now ranges from the radiologically isolated syndrome 1 to the different subtypes of established MS. 2 Epidemiological research is also not made easier by the fact that the diagnostic criteria for MS have changed multiple times from the Poser et al. 3 criteria, which included no clear definition of primary progressive multiple sclerosis (PPMS) and required two clinical relapses for a diagnosis of relapsing-remitting multiple sclerosis (RRMS), to the most recent MacDonald criteria which rely heavily on imaging findings for all subtypes of MS, 4 a technique that was unavailable when the major natural history cohorts were established.
Given this background, I believe that epidemiological studies can be useful to address a particular question in a particular setting. Also given this background, I fail to see the two opinions presented here as very controversial. Zhang and Tremlett's approach is about the risk and timing of developing secondary progression in a -hopefully large and representative -cohort of patients with RRMS, and the findings from such research can be helpful for counselling patients in the early stages of the disease. The underlying assumption here is that RRMS is driven by the same factors across the cohort, so that it is fair to say that all patients are 'at risk' of developing progression given enough time.
I see Vukusic's approach as an attempt to highlight and focus on the features of progressive MS, in particular on the differences and similarities of PPMS and secondary progressive multiple sclerosis (SPMS). Such studies are not necessarily useful for counselling patients at the onset of RRMS, but can help to understand the phenomenon of progression better.
The assumption here may be that progression is a possible outcome that not all RRMS patients are at risk for, but which affects only a subgroup of the whole population.
In the absence of clarity on whether either of these underlying assumptions is the only correct one, I believe that both approaches are valid and that both can increase our understanding of progression in MS.
However, it may be even more important to realize that epidemiological research -whichever way it is conducted -has its limits and will not give us a full understanding of progression. To get closer to understanding progression, and ultimately to be able to treat it, we will need a concerted effort that brings together research into the pathology, genetics, biochemistry, biomarkers, imaging findings and clinical outcome measures of progression in MS. I am hopeful that initiatives like the International Progressive MS alliance, and programmes by national MS societies directed at progressive MS, will bring us closer to these goals.
